Trial
NCT02885727
Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
—
Condition
Metastatic Pancreas Cancer
Intervention
Durvalumab
Why stopped
Funding issues caused the study to not be opened the at local IRB
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-12